Sofosbuvir

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Sofosbuvir

Examples of brand names: Sovaldi [EU/DE]

ATC code: J05AP08

Main use (for orientation): Hepatitis C

Documented research summary

Ledipasvir/sofosbuvir cohorts involving marijuana use report high virological cure rates. No isolated cannabinoid or sofosbuvir pharmacokinetics and no established safety of all combinations. Adherence associations observed in INCLUD are not causal.

Uncertainties and limitations

Combination regimens, different consumption patterns and confounders; no quantification of individual cannabinoids. Missing data do not establish safety.

Separately recorded findings

2 separately recorded findings. Each statement applies to its documented study context.

Cannabis; composition not quantified – insufficient data

Finding ID: B0457

Type of result: Concomitant-medication / consumption context; not an isolated drug–drug interaction

Observation: Observed drug / cannabis use was not associated with reduced treatment adherence or virological cure rates.

Mechanism: Observed treatment outcomes with ledipasvir/sofosbuvir during concomitant use

Study type: Secondary analysis of clinical HCV trials

Context studied: Ledipasvir/sofosbuvir with or without ribavirin; an ION-1 subgroup reported cannabis alone or other drugs. No isolated cannabinoid dose.

Clinical interpretation: Observational context, not evidence that interactions are absent.

Limitations and uncertainties: Multiple regimens and aggregated consumption groups; no sofosbuvir–CBD/THC pharmacokinetic evidence or general assurance of safety. Abstract reviewed.

Original sources for this finding: Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials. [VE_MED_27553375]

Cannabis / marijuana; composition not quantified – insufficient data

Finding ID: B0458

Type of result: Consumption / adherence context; not an isolated drug–drug interaction

Observation: High virological cure rate; marijuana use was statistically associated with fewer missed doses, not causally established as beneficial.

Mechanism: Observational association during ledipasvir/sofosbuvir treatment

Study type: Prospective HCV treatment cohort (INCLUD)

Context studied: 60 participants; 12 weeks of ledipasvir/sofosbuvir; marijuana reported at 60% of visits; SVR 52/60 in the intention-to-treat population.

Clinical interpretation: Limited clinical context, not blanket combination safety.

Limitations and uncertainties: No isolated cannabinoid / drug pharmacokinetics and substantial confounders; the adherence association is not a recommendation for consumption. Abstract reviewed.

Original sources for this finding: Adherence to Direct-Acting Antiviral Therapy in People Actively Using Drugs and Alcohol: The INCLUD Study. [VE_MED_33447634]

References and access status

[VE_LABEL_D0332] SOVALDI (SOFOSBUVIR) TABLET, FILM COATED SOVALDI (SOFOSBUVIR) PELLET [GILEAD SCIENCES, INC.]

Original source / bibliographic reference

Authors: Respective marketing authorisation holder; regulatory product information

Year: 2024

Source type: Product information / SmPC / US Prescribing Information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[VE_MED_27553375] Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.

Original source / bibliographic reference

Authors: Grebely J, Mauss S, Brown A, Bronowicki JP, Puoti M, Wyles D, Natha M, Zhu Y, Yang J, Kreter B, Brainard DM, Yun C, Carr V, Dore GJ.

Year: 2016

Source type: Clinical Trial, Phase III; Multicenter Study; Randomized Controlled Trial; Journal Article

DOI: 10.1093/cid/ciw580

PMID: 27553375

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

[VE_MED_33447634] Adherence to Direct-Acting Antiviral Therapy in People Actively Using Drugs and Alcohol: The INCLUD Study.

Original source / bibliographic reference

Authors: Brooks KM, Castillo-Mancilla JR, Morrow M, MaWhinney S, Rowan SE, Wyles D, Blum J, Huntley R, Salah LM, Tehrani A, Bushman LR, Anderson PL, Kiser JJ.

Year: 2021

Source type: research-article; Journal Article

DOI: 10.1093/ofid/ofaa564

PMID: 33447634

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility